Tyson Fury retirement: What will Anthony Joshua do next in 2025 as Eddie Hearn, Frank Warren discuss options Just as it looked like talks to finally make the long awaited Tyson Fury vs Anthony ...

Eddie Hearn has denied Anthony Joshua has agreed his next fight, saying the heavyweight is yet to begin talks with any opponent. Speculation on social media had suggested Joshua could fight Martin ...

Played by newcomer Joshua Hyunho Lee, Jin is introduced as a rival for Q (Anthony Keyvan), coming to K.I.S.S. and immediately stealing Q’s spot on the track team, setting the stage for an ...

As someone who has spent a lot of time in the high desert towns of Joshua Tree and Yucca Valley, I’ve long been skeptical of anyone who predicted that Twentynine Palms was about to become the ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the ...

Johnson & Johnson (NYSE:JNJ) fell ~3% in early trading on Wednesday, marking its biggest intraday drop since July 2023, even as the healthcare giant posted better-than-expected financials for Q4 ...

Joshua was brutally knocked out in his last fight against Dubois in September. Since then, 'Triple D' has been open to a rematch with 'AJ' and it looked likely that the pair will go toe-to-toe for ...

Yoshua Bengio is scientific director of the Quebec’s Mila A.I. Institute. Andrej Ivano/AFP via Getty Images Yoshua Bengio, a deep learning pioneer that has spent decades researching A.I., is ...

Liz Giuffre does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

Liverpool are not currently planning to make a move for Joshua Kimmich this year, while Manchester City and Barcelona are in the race for his signature, according to reports in Germany.

(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the ...

Countries that invest in building their artificial intelligence (AI) systems will have a geopolitical advantage in the future, said Canadian computer scientist and a pioneer of artificial neural ...